Second quarter net sales up 78% to $115.5 mil. for the period ended Feb. 28; pro forma net income increased 67% to $14.7 mil. Pro forma income reflects a tax provision for the recently acquired Richardson Labs prior to its purchase in January. Income results also reflect approximately $2.5 mil. in expenses related to the acquisition. Sales to retailers rose 95% during the quarter and the Rexall Showcase International direct sales division posted a 61% gain. The company said its Osteo Bi-Flex product "remains the third best selling nutritional supplement in the country" and its Sundown herbals line is the number one selling herbals line in U.S. food, drug and mass market outlets. The company also announced retirement of Dean DeSantis as chief operating officer to pursue other interests. A successor has not yet been named...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The Pink Sheet takes an exclusive look at the complete response letter, which shows the information on application deficiencies that could become widely available if FDA leaders succeed in releasing CRLs in real time.
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.